Tags

Type your tag names separated by a space and hit enter

Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
J Clin Psychiatry. 1990 Sep; 51 Suppl:31-9.JC

Abstract

The authors reviewed pharmacologic treatment of generalized anxiety disorder (GAD), particularly treatment with benzodiazepine agents, and compared the antianxiety effects and dependence risks of these agents with those of nonGABAergic compounds such as buspirone--a new psychotropic drug--in the treatment of chronic anxiety. Forty outpatients who met DSM-III criteria for GAD were randomly assigned to double-blind treatment with buspirone or lorazepam. After 8 weeks, treatment was abruptly stopped and withdrawal reactions were evaluated at Weeks 9 and 10. After 3 to 4 weeks, buspirone's efficacy in treating GAD symptomatology was found to be comparable with lorazepam's, except for sleep disturbances, which were minimally affected by buspirone. After treatment was discontinued, buspirone-treated patients were free from withdrawal symptoms, while the symptoms of lorazepam-treated patients worsened at Week 9.

Authors+Show Affiliations

Institute of Clinical Psychiatry, University of Pisa, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Review

Language

eng

PubMed ID

2211564

Citation

Petracca, A, et al. "Treatment of Generalized Anxiety Disorder: Preliminary Clinical Experience With Buspirone." The Journal of Clinical Psychiatry, vol. 51 Suppl, 1990, pp. 31-9.
Petracca A, Nisita C, McNair D, et al. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry. 1990;51 Suppl:31-9.
Petracca, A., Nisita, C., McNair, D., Melis, G., Guerani, G., & Cassano, G. B. (1990). Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. The Journal of Clinical Psychiatry, 51 Suppl, 31-9.
Petracca A, et al. Treatment of Generalized Anxiety Disorder: Preliminary Clinical Experience With Buspirone. J Clin Psychiatry. 1990;51 Suppl:31-9. PubMed PMID: 2211564.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. AU - Petracca,A, AU - Nisita,C, AU - McNair,D, AU - Melis,G, AU - Guerani,G, AU - Cassano,G B, PY - 1990/9/1/pubmed PY - 1990/9/1/medline PY - 1990/9/1/entrez SP - 31 EP - 9 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 51 Suppl N2 - The authors reviewed pharmacologic treatment of generalized anxiety disorder (GAD), particularly treatment with benzodiazepine agents, and compared the antianxiety effects and dependence risks of these agents with those of nonGABAergic compounds such as buspirone--a new psychotropic drug--in the treatment of chronic anxiety. Forty outpatients who met DSM-III criteria for GAD were randomly assigned to double-blind treatment with buspirone or lorazepam. After 8 weeks, treatment was abruptly stopped and withdrawal reactions were evaluated at Weeks 9 and 10. After 3 to 4 weeks, buspirone's efficacy in treating GAD symptomatology was found to be comparable with lorazepam's, except for sleep disturbances, which were minimally affected by buspirone. After treatment was discontinued, buspirone-treated patients were free from withdrawal symptoms, while the symptoms of lorazepam-treated patients worsened at Week 9. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/2211564/Treatment_of_generalized_anxiety_disorder:_preliminary_clinical_experience_with_buspirone_ L2 - http://www.diseaseinfosearch.org/result/7698 DB - PRIME DP - Unbound Medicine ER -